Vaccine weekly最新文献

英文中文

Vaccination efforts lauded in Brazil. 巴西赞扬疫苗接种工作。

Vaccine weekly

Pub Date : 1994-12-19

引用次数: 0

Women's issues. Worldwide they face greatest HIV risk. 女性的问题。在世界范围内，他们面临着最大的艾滋病毒风险。

Vaccine weekly

Pub Date : 1994-12-12

引用次数: 0

Thai volunteers test HIV vaccine. 泰国志愿者测试艾滋病毒疫苗。

Vaccine weekly

Pub Date : 1994-12-12

A group of 30 Thai volunteers received their final injections in a multi-national test of what doctors believe is a promising experimental AIDS vaccine. Dr. Prapan Panupark, director of the project in Thailand, said he was encouraged by initial results of the test conducted on 25 males and five females. The study of the experimental vaccine, known as the United Biomedical Inc. synthetic monovalent HIV-1 peptide, involved healthy volunteers aged from 21 to 48. Prapan told a press conference that participants received their first injections on June 6, 1994, another on July 4, 1994, and their final shot November 28, 1994. He said similar tests are taking place in Brazil and Uganda, which, like Thailand, have been hard-hit by HIV. One month after the second injection, Prapan said, blood tests revealed that out of 24 volunteers receiving the vaccine, 10 had developed immunity. "We are happy that immunity developed in 10 cases out of 24, or over 40%," he said. "We are happy because in similar tests in other countries, such as the US and Australia, only about 20% of the volunteers developed immunity." He said the volunteers will have their blood tested three more times to determine their levels of immunity. According to recently released figures, 3902 people have died of AIDS in Thailand in the past decade. Another 5215 patients are suffering from advanced AIDS in Thailand, while an estimated 600,000 people are believed to be HIV-positive.

30名泰国志愿者接受了最后一次注射，医生们认为这是一种很有前途的实验性艾滋病疫苗。泰国项目负责人帕潘·帕努帕克(Prapan Panupark)博士说，他对25名男性和5名女性进行的初步测试结果感到鼓舞。这种实验性疫苗被称为联合生物医学公司合成单价HIV-1肽，研究对象是年龄在21岁至48岁之间的健康志愿者。普拉潘在新闻发布会上说，参与者在1994年6月6日接受了第一次注射，在1994年7月4日接受了第二次注射，在1994年11月28日接受了最后一次注射。他说，巴西和乌干达也在进行类似的检测，这两个国家和泰国一样，都是艾滋病的重灾区。Prapan说，在第二次注射一个月后，血液测试显示，在24名接种疫苗的志愿者中，有10人产生了免疫力。他说:“我们很高兴在24个病例中有10个产生了免疫力，即超过40%。”“我们很高兴，因为在美国和澳大利亚等其他国家进行的类似测试中，只有约20%的志愿者产生了免疫力。”他说，志愿者将再接受三次血液检测，以确定他们的免疫水平。根据最近公布的数据，在过去的十年里，泰国有3902人死于艾滋病。泰国还有5215名艾滋病晚期患者，据估计有60万人被认为是艾滋病毒阳性。

{"title":"Thai volunteers test HIV vaccine.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"A group of 30 Thai volunteers received their final injections in a multi-national test of what doctors believe is a promising experimental AIDS vaccine. Dr. Prapan Panupark, director of the project in Thailand, said he was encouraged by initial results of the test conducted on 25 males and five females. The study of the experimental vaccine, known as the United Biomedical Inc. synthetic monovalent HIV-1 peptide, involved healthy volunteers aged from 21 to 48. Prapan told a press conference that participants received their first injections on June 6, 1994, another on July 4, 1994, and their final shot November 28, 1994. He said similar tests are taking place in Brazil and Uganda, which, like Thailand, have been hard-hit by HIV. One month after the second injection, Prapan said, blood tests revealed that out of 24 volunteers receiving the vaccine, 10 had developed immunity. \"We are happy that immunity developed in 10 cases out of 24, or over 40%,\" he said. \"We are happy because in similar tests in other countries, such as the US and Australia, only about 20% of the volunteers developed immunity.\" He said the volunteers will have their blood tested three more times to determine their levels of immunity. According to recently released figures, 3902 people have died of AIDS in Thailand in the past decade. Another 5215 patients are suffering from advanced AIDS in Thailand, while an estimated 600,000 people are believed to be HIV-positive.","PeriodicalId":85829,"journal":{"name":"Vaccine weekly","volume":" ","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"1994-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22039116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology / vaccine efficacy trials. "HIV Incidence in Adults in Northern Thailand". 流行病学/疫苗功效试验。“泰国北部成人艾滋病毒发病率”。

Vaccine weekly

Pub Date : 1994-10-10

C Khamboonruang, C Beyrer, C Natpatan, S Eiumtrakol, D Celentano, K E Nelson

Unlabelled: According to an abstract submitted by the authors to the X International Conference on AIDS, held August 7-12, 1994, in Yokohama, Japan, "

Objective: To measure the HIV-1 incidence, follow-up rates and high risk behaviors in cohorts of seronegative adults in northern Thailand.

Methods: We screened cohorts of female commercial sex workers (CSWs), male STD clinic patients, Royal Thai Army (RTA) conscripts, and discharged RTA conscripts at baseline and q3 to 6 months for HIV infection by ELISA and WB and did interviews for high risk behavior, medical history, and STD cultures.

Results: Of 1068 CSWs, 409 (38.3%) were HIV positive, and 396 HIV negative were enrolled in the study; follow-up at 6 months was 70.7% and 19 seroconverted, for an incidence of 12.8/100 person years. Of 1031 male STD patients, 164 (15.9%) were HIV positive, and 264 HIV negative (30.4%) were enrolled; follow-up at 6 months was 91.9% and 6 seroconverted, for an incidence of 4.92/100 person years. Of 969 RTA conscripts, 12.4% were HIV positive at baseline and 90% were followed at 6 months; 3 of 778 seroconverted, for an incidence of 0.87/100 person years. (Previous RTA cohorts have had an incidence of 3.4%/year). Among 380 men discharged from RTA, follow-up at 9 months was 81.8% and the incidence was 5.2/100 person years. Sample sizes required to show an HIV vaccine efficacy of 60%, with a power-.90, alpha-.05 varies from CSUs 644, STD patients 1456 to ex-RTA-1306.

Conclusions: Several populations in northern Thailand appear to have sufficiently high HIV-1 incidence and adequate follow-up for HIV vaccine efficacy trials and other preventive intervention trials.

未标记:根据作者提交给1994年8月7日至12日在日本横滨举行的第X届国际艾滋病会议的摘要，“目的:测量泰国北部血清阴性成人队列中HIV-1的发病率、随访率和高危行为。方法:采用ELISA和WB对女性商业性工作者(CSWs)、男性性病门诊患者、泰国皇家军队(RTA)义务兵和退伍RTA义务兵在基线和第3 ~ 6个月进行HIV感染筛查，并对高危行为、病史和性病培养进行访谈。结果:1068名CSWs中，409名(38.3%)HIV阳性，396名HIV阴性入组;随访6个月为70.7%，19例血清转化，发病率为12.8/100人年。1031例男性性病患者中，HIV阳性164例(15.9%)，HIV阴性264例(30.4%);6个月随访率为91.9%，6例血清转化，发病率为4.92/100人年。在969名RTA征召者中，12.4%在基线时为HIV阳性，90%在6个月时随访;778例血清转化为3例，发病率为0.87/100人年。(以前的RTA队列的发病率为3.4%/年)。从RTA出院的380名男性中，9个月随访率为81.8%，发病率为5.2/100人年。样本量要求显示艾滋病毒疫苗的效力为60%，幂-。90年,α-。05从CSUs 644，性病患者1456到前rta -1306不等。结论:泰国北部的几个人群似乎有足够高的HIV-1发病率和足够的随访来进行HIV疫苗有效性试验和其他预防性干预试验。

{"title":"Epidemiology / vaccine efficacy trials. \"HIV Incidence in Adults in Northern Thailand\".","authors":"C Khamboonruang, C Beyrer, C Natpatan, S Eiumtrakol, D Celentano, K E Nelson","doi":"","DOIUrl":"","url":null,"abstract":"Unlabelled: According to an abstract submitted by the authors to the X International Conference on AIDS, held August 7-12, 1994, in Yokohama, Japan, \"Objective: To measure the HIV-1 incidence, follow-up rates and high risk behaviors in cohorts of seronegative adults in northern Thailand.Methods: We screened cohorts of female commercial sex workers (CSWs), male STD clinic patients, Royal Thai Army (RTA) conscripts, and discharged RTA conscripts at baseline and q3 to 6 months for HIV infection by ELISA and WB and did interviews for high risk behavior, medical history, and STD cultures.Results: Of 1068 CSWs, 409 (38.3%) were HIV positive, and 396 HIV negative were enrolled in the study; follow-up at 6 months was 70.7% and 19 seroconverted, for an incidence of 12.8/100 person years. Of 1031 male STD patients, 164 (15.9%) were HIV positive, and 264 HIV negative (30.4%) were enrolled; follow-up at 6 months was 91.9% and 6 seroconverted, for an incidence of 4.92/100 person years. Of 969 RTA conscripts, 12.4% were HIV positive at baseline and 90% were followed at 6 months; 3 of 778 seroconverted, for an incidence of 0.87/100 person years. (Previous RTA cohorts have had an incidence of 3.4%/year). Among 380 men discharged from RTA, follow-up at 9 months was 81.8% and the incidence was 5.2/100 person years. Sample sizes required to show an HIV vaccine efficacy of 60%, with a power-.90, alpha-.05 varies from CSUs 644, STD patients 1456 to ex-RTA-1306.Conclusions: Several populations in northern Thailand appear to have sufficiently high HIV-1 incidence and adequate follow-up for HIV vaccine efficacy trials and other preventive intervention trials.","PeriodicalId":85829,"journal":{"name":"Vaccine weekly","volume":" ","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"1994-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"22037719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contraceptive vaccines. Birth-control vaccine feasible, but more work needed. 避孕疫苗。控制生育的疫苗是可行的，但需要做更多的工作。

Vaccine weekly

Pub Date : 1994-09-26

引用次数: 0

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Vaccine weekly

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀